[HTML][HTML] Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies
D Chen, F You, S Xiang, Y Wang, Y Li… - American Journal of …, 2021 - ncbi.nlm.nih.gov
The great success of chimeric antigen receptor T (CAR-T)-cell therapy in B-cell
malignancies has significantly promoted its rapid expansion to other targets and indications …
malignancies has significantly promoted its rapid expansion to other targets and indications …
[HTML][HTML] A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia
F You, Y Wang, L Jiang, X Zhu, D Chen… - American journal of …, 2019 - ncbi.nlm.nih.gov
Chimeric antigen receptor (CAR) immunotherapy has recently shown promise in clinical
trials for B-cell malignancies; however, designing CARs for T-cell based diseases remain a …
trials for B-cell malignancies; however, designing CARs for T-cell based diseases remain a …
Feasibility study of a novel preparation strategy for anti-CD7 CAR-T cells with a recombinant anti-CD7 blocking antibody
J Ye, Y Jia, IJ Tuhin, J Tan, MA Monty, N Xu… - Molecular Therapy …, 2022 - cell.com
Although chimeric antigen receptor (CAR) T cell immunotherapy has shown promising
significance in B cell malignancies, success against T cell malignancies remains …
significance in B cell malignancies, success against T cell malignancies remains …
Targeting CD5 chimeric antigen receptor-engineered natural killer cells against T-cell malignancies
Y Zu, Q Ren, J Zhang, H Su, Q Lu, Y Song… - … Hematology & Oncology, 2024 - Springer
Chimeric antigen receptor engineered T cells (CAR-T) have demonstrated promising clinical
efficacy in B-cell malignancies, and the approach has been extended to T-cell malignancies …
efficacy in B-cell malignancies, and the approach has been extended to T-cell malignancies …
[HTML][HTML] Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia
T Zhang, T Wang, F You, Z Li, D Chen, K Zhang… - Transplant …, 2022 - Elsevier
Chimeric antigen receptor (CAR) T-cell immunotherapies targeting CD19 can achieve
impressive clinical remission rates in the treatment of B-cell non-Hodgkin lymphoma and B …
impressive clinical remission rates in the treatment of B-cell non-Hodgkin lymphoma and B …
[HTML][HTML] Naturally selected anti-CD7 CAR-T cells without additional genetic manipulations as a potentially superior therapy for T-cell malignancies
Y Liu, W Li, L Wang, M Ba, Q Wang, P Lu, L Liu, J Li - Blood, 2021 - Elsevier
Abstract Introduction To prevent CAR-T fratricide, anti-CD7 CAR (7CAR) T cells used for
treating T-cell malignancies are often modified by CD7 ablation via CRISPR/CAS9 gene …
treating T-cell malignancies are often modified by CD7 ablation via CRISPR/CAS9 gene …
Engineering naturally occurring CD7− T cells for the immunotherapy of hematological malignancies
A Freiwan, JT Zoine, JC Crawford… - Blood, The Journal …, 2022 - ashpublications.org
Chimeric antigen receptor (CAR) T-cell therapy targeting T-cell acute lymphoblastic
leukemia (T-ALL) faces limitations such as antigen selection and limited T-cell persistence …
leukemia (T-ALL) faces limitations such as antigen selection and limited T-cell persistence …
Robust antitumor activity and low cytokine production by novel humanized anti-CD19 CAR T cells
Recent studies have described the remarkable clinical outcome of anti-CD19 chimeric
antigen receptor (CAR) T cells in treating B-cell malignancies. However, over 50% of …
antigen receptor (CAR) T cells in treating B-cell malignancies. However, over 50% of …
Universal anti-CD7 CAR-T cells targeting T-ALL and functional analysis of CD7 antigen on T/CAR-T cells
L Xie, R Gu, X Yang, S Qiu, Y Xu, J Mou, Y Wang… - Blood, 2022 - ashpublications.org
Background Patients with relapsed/refractory acute T lymphoblastic leukemia (T-ALL) suffer
from unsatisfactory prognosis and limited treatment options. Recently, the application of …
from unsatisfactory prognosis and limited treatment options. Recently, the application of …
CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies
D Gomes-Silva, M Srinivasan, S Sharma… - Blood, The Journal …, 2017 - ashpublications.org
Extending the success of chimeric antigen receptor (CAR) T cells to T-cell malignancies is
problematic because most target antigens are shared between normal and malignant cells …
problematic because most target antigens are shared between normal and malignant cells …